Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 18/20 | 0.82 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18554007 | 0.90 | TLR8 (1.00) | TLR8TLR7KDM4EALDH1A1GAA | |
| SCHEMBL18553992 | 0.89 | TLR8 (1.00) | TLR8TLR7 | |
| Hydrochloric Acid SCHEMBL18554031 | 0.89 | TLR8 (1.00) | TLR8TLR7KDM4EALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL18554051 | 0.87 | TLR8 (1.00) | TLR8TLR7 | |
| SCHEMBL16836314 | 0.87 | TLR8 (0.79) | TLR8TLR7KDM4EALDH1A1GAA | |
| SCHEMBL16836321 | 0.86 | TLR8 (0.74) | TLR8TLR7 | |
| SCHEMBL18593892 | 0.84 | TLR8 (1.00) | TLR8TLR7 | |
| SCHEMBL16836395 | 0.83 | TLR8 (0.74) | TLR8TLR7KDM4EALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL18554099 | 0.83 | TLR8 (0.79) | TLR8TLR7KDM4EALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL18554050 | 0.83 | TLR8 (1.00) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1476429-B1 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2005-11-16 | — | — | EP | disclosed |
| EP-1476429-A1 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068748-A9 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-10-07 | — | — | WO | disclosed |
| US-6800650-B2 | FOR THERAPY AND PROPHYLAXIS OF DIABETES, PARTICULARLY NON-INSULIN DEPENDENT DIABETES MELLITUS AND IMPAIRED GLUCOSE TOLERANCE. | HOFFMANN-LA ROCHE INC. | 2004-10-05 | — | — | US | disclosed |
| US-20030195188-A1 | Pyridine and quinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-16 | — | — | US | disclosed |
| WO-2003068748-A1 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195188-A1 | Pyridine and quinoline derivatives | DPP4, DPP3, DPP7 | TLR8 3182/4885TLR7 996/4885KDM4E 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.